National Liver Cancer Screening Trial
Finding liver cancer early is important to increase chances of getting treatment and decreasing risk of dying from cancer. The purpose of this research is to compare the effectiveness of two liver cancer screening methods to detect liver cancer at an early stage. Participants will be randomly (by chance) placed in one of two study groups – one group will undergo ultrasound imaging of the liver with or without a blood test to measure a specific protein, whereas the second group will undergo a blood test for liver cancer screening called a GALAD score. The GALAD score combines three blood tests to screen for liver cancer. We do not currently know if GALAD would help detect liver cancer earlier than standard screening.
• 18 to 85 years old
• diagnosis of cirrhosis of the liver of any cause, or Hepatitis B
• physician has determined patient is eligible for for hepatocellular carcinoma (HCC) screening
• history or clinical symptoms of hepatocellular carcinoma or cholangiocarcinoma
• presence of another active cancer in the past 2 years
• history of an organ transplant
• currently on the liver transplant list
• diagnosis of alcoholic cirrhosis in the past 3 months
• women who are pregnant
• currently taking warfarin
Cancer
HCC, hepatocellular carcinoma, Liver Cancer, Clinics and Surgery Center (CSC)